Comparison of the Diagnostic Accuracy of Brain Natriuretic Peptide (BNP) and the N-terminal Part of the Propeptide of BNP Immunoassays in Chronic and Acute Heart Failure: a Systematic Review

Overview

Journal Clin Chem

Publisher Oxford University Press

Specialty Biochemistry

Date 2007 Mar 27

PMID 17384013

Citations 33

Authors

Aldo Clerico

Marianna Fontana

Luc Zyw

Claudio Passino

Michele Emdin

Affiliations

Soon will be listed here.

Abstract

Background: We used evidence-based laboratory medicine principles to compare the diagnostic accuracy of brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP (NT-proBNP) assays for the diagnosis of heart failure.

Methods: In May 2006, we performed a computerized literature search of the online National Library of Medicine to select studies specifically designed to compare the diagnostic accuracy of BNP and NT-proBNP assays. The comparison took into account the area under the curve and diagnostic odds ratio (DOR) derived from ROC analysis of original studies.

Results: Both BNP and NT-proBNP assays were found to be clinically useful for the diagnosis of heart failure. Metaanalysis of these data was difficult because of the heterogeneity of data regarding patient population, diagnostic criteria, end-points, and immunoassay methods for both BNP and NT-proBNP. Separate metaanalyses were performed for acute and chronic heart failure. In chronic heart failure, the diagnostic DOR for BNP (8.44, 95% CI 4.66-15.30) was not significantly different from that of NT-proBNP (23.36, 95% CI 9.38-58.19). In patients with acute heart failure, the mean DOR for BNP (16.46, 95% CI 10.65-25.43) was not significantly different from that of NT-proBNP (18.61, 95% CI 12.99-26.65).

Conclusion: Our results indicate that both BNP and NT-proBNP assays have a high degree of diagnostic accuracy and clinical relevance for both acute and chronic heart failure.

Citing Articles

New Insights in the Era of Clinical Biomarkers as Potential Predictors of Systemic Therapy-Induced Cardiotoxicity in Women with Breast Cancer: A Systematic Review.

Alexandraki A, Papageorgiou E, Zacharia M, Keramida K, Papakonstantinou A, Cipolla C Cancers (Basel). 2023; 15(13).

PMID: 37444400 PMC: 10340234. DOI: 10.3390/cancers15133290.

Brain natriuretic peptide and N-terminal brain natriuretic peptide for the diagnosis of haemodynamically significant patent ductus arteriosus in preterm neonates.

Gokulakrishnan G, Kulkarni M, He S, Leeflang M, Cabrera A, Fernandes C Cochrane Database Syst Rev. 2022; 12:CD013129.

PMID: 36478359 PMC: 9730301. DOI: 10.1002/14651858.CD013129.pub2.

Prognostic value and clinical utility of NT-proBNP in acute emergency medical admissions.

Conway R, Byrne D, ORiordan D, Silke B Ir J Med Sci. 2022; 192(4):1939-1946.

PMID: 36279040 DOI: 10.1007/s11845-022-03198-1.

B-Type Natriuretic Peptide (BNP) Revisited-Is BNP Still a Biomarker for Heart Failure in the Angiotensin Receptor/Neprilysin Inhibitor Era?.

Nishikimi T, Nakagawa Y Biology (Basel). 2022; 11(7).

PMID: 36101415 PMC: 9312360. DOI: 10.3390/biology11071034.

Protocol for a systematic review and meta-analysis of studies on the use of brain natriuretic peptide and N-terminal brain natriuretic peptide levels in the diagnosis of cardiopulmonary edema in acute respiratory failure.

Terayama T, Taniguchi T, Imai R, Anan K, Yoshida T, Ando K Syst Rev. 2021; 10(1):314.

PMID: 34911558 PMC: 8675464. DOI: 10.1186/s13643-021-01869-1.